Healthcare

Tenet Healthcare runs hospitals and a large outpatient surgery network, giving it exposure to essential care and the long-term shift toward lower-cost settings. Strong cash flow, improved margins, and a more focused operating model make it a company worth a closer look.

Teva is a global drugmaker combining large-scale generics with a growing branded portfolio led by Austedo, Ajovy, and Uzedy. Cash flow and profitability have improved, making the company’s multi-year repair effort more substantial and worth a closer look.

Stryker is a major medical device company spanning orthopedics, surgical equipment, and neurotechnology. Strong margins, rising cash flow, and durable procedure demand make its long-term business profile compelling, even with a premium valuation.

STERIS provides sterilization, infection prevention, and surgical support across hospitals, medical devices, and life sciences. Rising cash flow, stronger margins, and a broader recurring-revenue base make its long-term profile worth a closer look.

Revolution Medicines is building targeted cancer drugs for major RAS-driven tumors, a field with large unmet need and substantial commercial potential. Its rising profile comes from a broad KRAS-focused pipeline, though today’s valuation leans heavily on future clinical success.

Royalty Pharma turns drug royalties into a scalable healthcare cash-flow platform. High margins, resilient free cash flow, and leadership in a specialized niche make it a distinctive business worth a closer look.

ResMed builds sleep apnea and respiratory devices, replacement masks, and care software. The company combines recurring demand, strong margins, low leverage, and expanding cash flow with exposure to long-term trends in diagnosis, home care, and connected healthcare.